Clearside Biomedical Inc(CLSD)stock report

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.

Finance:
Market Cap:129.2M; Shares Outstanding:41.1M; Q3 2019(9/30/19): Cash 22.55M. Loss 6.53M

EPS and Sales:
https://finance.yahoo.com/quote/CLSD/financials?p=CLSD

Date EPS % last year % last quarter
2018.12.31 -2.58 -10.86% -84.50%
2019.3.31 -0.42 19.43% 83.72%
2019.6.30 -0.56 51.74% -33.33%
2019.9.30 -0.73 61.64% 30.36%

 

Date Sales % last year % last quarter
2018.12.31 0.03M -91.30% /
2019.3.31 0.05M / 66.67%
2019.6.30 0.09M / 80.00%
2019.9.30 0.23M / 155.56%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=CLSD&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/CLSD/institutional-ownership/

2019.12.28:
Total institutions: 56,no change
Shares hold: 7101k shares. no change
shares% hold: 17.26%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/CLSD/price-targe

Leave a Reply